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Abstract
Background: In malaria-endemic countries, large proportions of individuals infected with Plasmodium falciparum
are asymptomatic and constitute a reservoir of parasites for infection of newly hatched mosquitoes.
Methods: Two studies were run in parallel in Burkina Faso to evaluate the impact of systematic identification and
treatment of asymptomatic carriers of P. falciparum, detected by rapid diagnostic test, on disease transmission and
susceptibility to clinical malaria episodes. A clinical study assessed the incidence of symptomatic malaria episodes
with a parasite density >5,000/μL after three screening and treatment campaigns ~1 month apart before the rainy
season; and an entomological study determined the effect of these campaigns on malaria transmission as
measured by entomological inoculation rate.
Results: The intervention arm had lower prevalence of asymptomatic carriers of asexual parasites and lower
prevalence of gametocyte carriers during campaigns 2 and 3 as compared to the control arm. During the entire
follow-up period, out of 13,767 at-risk subjects, 2,516 subjects (intervention arm 1,332; control arm 1,184) had
symptomatic malaria. Kaplan-Meier analysis of the incidence of first symptomatic malaria episode with a parasite
density >5,000/μL showed that, in the total population, the two treatment arms were similar until Week 11–12 after
campaign 3, corresponding with the beginning of the malaria transmission season, after which the probability of
being free of symptomatic malaria was lower in the intervention arm (logrank p < 0.0001). Similar trends were
observed in infants and children <5 years and in individuals ≥5 years of age. In infants and children <5 years old
who experienced symptomatic malaria episodes, the geometric mean P. falciparum density was lower in the
intervention arm than the control arm. This trend was not seen in those individuals aged ≥5 years. Over the year,
monthly variation in mosquito density and entomological inoculation rate was comparable in both arms, with
September peaks in both indices.
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Conclusion: Community screening and targeted treatment of asymptomatic carriers of P. falciparum had no effect
on the dynamics of malaria transmission, but seemed to be associated with an increase in the treated community’s
susceptibility to symptomatic malaria episodes after the screening campaigns had finished. These results highlight
the importance of further exploratory studies to better understand the dynamics of disease transmission in the
context of malaria elimination.
Keywords: Malaria, Plasmodium falciparum, Asymptomatic carriers, Community screening, Entomological
inoculation rate, Parasite density, Disease transmission
Background
In 2010, as many as 1.2 million individuals are estimated
to have died from malaria, revealing the considerable
burden that this disease continues to place on many en-
demic areas in sub-Saharan Africa [1]. However, in con-
trast to this trend, a number of countries in this region
have experienced a decline in malaria transmission over
the past decade due to the implementation of sustained
malaria control and prevention strategies [2-6]. Follow-
ing these promising results, stakeholders within the
malaria community have begun to consider malaria
elimination in certain epidemiological settings [7,8]. Ap-
propriate strategies for drug use in an elimination con-
text have consequently been a subject of discussion, with
mass drug administration (MDA) and systematic screen-
ing for parasite carriage followed by treatment being
reviewed [9,10].
MDA involves the administration of antimalarials to
entire populations without knowledge of who is infected.
In countries with high malaria endemicity, the majority
of MDA programs have failed in their attempts to inter-
rupt transmission or provided only a transient success
[11,12]. Given the lack of evidence for sustained success,
the fear that widespread use of antimalarials in these
programs could speed up the development of parasite
resistance and the potential high economic cost of such
interventions, MDA is not currently recommended by
the World Health Organization [13].
Screening and treatment only of infected individuals is
an alternative to MDA. In malaria-endemic countries, a
large proportion of Plasmodium falciparum infections
are asymptomatic [14-16]. As a consequence, the sys-
tematic identification and treatment of asymptomatic
carriers could potentially decrease disease transmission
by reducing the pool of parasites carried by these indi-
viduals [17,18]. A recent simulation suggests that mass
screening and treatment could be a cost-effective inter-
vention in areas with medium-to-high levels of transmis-
sion that have achieved moderate coverage with
insecticide-treated nets [19].
The description of the epidemiology of malaria is often
focused on clinical parameters such as prevalence of
parasitemia. However, entomological information such
as vector species composition and density, proportion of
infected mosquitoes, entomological inoculation rate
(EIR), and insecticide resistance status are key transmis-
sion parameters essential to the planning of control
measures. This article reports results from two studies
run in parallel: a clinical study to evaluate the impact of
systematic treatment of P. falciparum asymptomatic car-
riers at a community level on the incidence of symptom-
atic malaria episodes with a parasite density >5,000/μL;
and an entomological study to determine the effect of
the screening and treatment intervention on malaria
transmission as measured by EIR. The studies took place
in the health district of Saponé, about 50 km south of
Ouagadougou in Burkina Faso, which is an area with
marked seasonal P. falciparum malaria transmission
from June to November [20]. The null hypothesis in this
study was that there would be no difference in terms of
EIR between the intervention (mass screening and treat-




The full study methodology was published by Tiono et al.
[21]. A brief summary of the methodology is given here.
This was a single-center, controlled, parallel, cluster-
randomized study that evaluated the effect of systematic
treatment of P. falciparum asymptomatic carriers on the
incidence of symptomatic malaria episodes in children
(<5 years) and adults over a 12-month period after com-
pletion of three community screening and treatment
campaigns, compared with no treatment of asymptom-
atic carriers. In total, 18 clusters (each comprising one
village) were randomized and assigned in a 1:1 ratio to
the intervention or control arm.
Before the study implementation phase, all inhabitants
of the 18 clusters were provided with long-lasting
insecticide-treated nets (LLINs; OLYSET® nets [Sumi-
tomo Chemical Co, Ltd, Tokyo, Japan]). Compliance
with mosquito net use was checked every two months
during home visits to the trial participants by Demo-
graphic Surveillance System (DSS) fieldworkers.
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During the implementation phase, inhabitants of the
intervention and control clusters participated in the
three screening campaigns that took place ~1 month
apart between January and April 2011, before the start
of the rainy season. A fourth campaign was conducted
in January 2012 after the rainy season had ended to
mark the end of the study at ~12 months (Figure 1). At
each campaign, finger-prick blood samples were taken
from the entire study population in the intervention arm
and a randomly selected 40% in the control arm for
microscopic screening for P. falciparum asexual forms
and gametocytes. In the intervention arm, the popula-
tion was also screened using a rapid diagnostic test
(RDT; First Response® Malaria Ag, Premier Medical
Corp Ltd., Nani-Daman, India) to identify asymptomatic
carriers. Those individuals with a positive RDT received
treatment with artemether-lumefantrine (20 mg arte-
mether and 120 mg lumefantrine [Coartem®, Novartis
Pharma AG, Basel, Switzerland]) or artemether-
lumefantrine dispersible, twice a day for three consecu-
tive days. Subjects in the control arm were not screened
by RDT – microscopy alone with delayed reading was
used to ensure that study personnel and screened sub-
jects remained unaware of subject status.
Following the third screening campaign, study partici-
pants in both arms were followed up for passive detec-
tion of symptomatic malaria throughout the wet season,
when malaria transmission is high. Participants were en-
couraged to report to their local healthcare facility or
clinic as soon as they felt unwell. An RDT was per-
formed for all participants attending the local healthcare
facility with confirmed fever (axillary temperature
≥37.5°C) or history of fever within the last 24 hours. On
day 1 of campaign 4, a blood sample was also collected
for gametocyte assessment by quantitative reverse
transcription-polymerase chain reaction (qRT-PCR),
which was conducted in 1,999 randomly selected sub-
jects drawn from the entire intervention group and a
40% subgroup of the control population. In this study, a
case of symptomatic malaria was defined as fever or his-
tory of fever within the previous 24 hours and a P. fal-
ciparum asexual parasite count >5,000/μL. Each episode
of symptomatic malaria was treated and the patient
followed up at day 7. Parasitological cure was assessed
by microscopy for each symptomatic malaria episode
on day 7.
The blood films obtained during visits and for symp-
tomatic malaria assessment were air-dried and Giemsa-
stained for examination by a light microscope fitted with
a 100 X oil immersion lens at a single laboratory. At
least 200 thick film fields were examined before a slide
was declared negative. When P. falciparum was present,
a count of the asexual forms against leukocytes was
made using a tally counter. Counting was done based on
Figure 1 Single-center, controlled, parallel, cluster-randomized, 12-month prospective study. Reproduced from Tiono et al. 2013 [21].
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at least 200 leukocytes according to WHO standards. If
less than 10 parasites were identified from the 200
leukocyte screen, counting was extended to 1,000 leuko-
cytes. If P. falciparum gametocytes were seen, a gameto-
cyte count was performed against 1,000 leukocytes. All
slides were read by two independent microscopists. If
the ratio of densities from the first two readings was
>1.5 or <0.67, or if less than 30 parasites were counted
with an absolute difference of more than 10 in the num-
ber of parasites, the slide was evaluated by a third micro-
scopist. The definitive result was the mean of the
parasite density of the two most concordant reading
results.
Microscopist competency was evaluated through two
equivalent quality control (EQC) programs. The first EQC
was carried out by College of American Pathology profi-
ciency testing and included a set of 5 slides provided to
each microscopist for reading thrice a year. The second
EQC was performed by WHO (National Institute for
Communicable Diseases) and involved the reading of a set
of 20 slides every quarter by each microscopist. Only those
with a score of at least 80%, graded as ‘competent’, were
involved in the reading of trial participants’ slides.
This trial is registered with ClinicalTrials.gov, number
NCT01256658.
Ethics section
The protocol and the proposed informed consent form
were reviewed and approved by the Centre National de
Recherche et de Formation sur le Paludisme Institutional
Review Board and by the National Ethical Committee
for Health Research of Burkina Faso. Prior to study initi-
ation, a community meeting was held in each of the se-
lected clusters to discuss the study with the community.
The freedom of each individual household and house-
hold member to decide on participation was discussed
to minimize the potential influence of key opinion
leaders in each cluster. Individual informed consent was
obtained from each participant during a visit to the
household before any study procedure.
Entomology study methods
Mosquito collection and processing
From the 18 clusters selected for the clinical study, 10
were randomly selected for the entomology study. To
achieve random selection, two lists containing the nine
villages from each arm were generated. Using the ran-
dom function in Excel (Microsoft Corporation, Red-
mond, WA), each village on the intervention list and the
control list was assigned a number between 1 and 9. The
villages in each arm were then listed in ascending order
on the basis of the randomly assigned number. The first
five villages from each list were selected for inclusion in
the entomology study.
Beginning at the initiation of the first screening cam-
paign and continuing weekly until screening campaign 4
(i.e. ~12 months later), mosquitoes were collected from
10 randomly selected houses in each of the 10 selected
clusters. To randomly select the houses for mosquito
collection, a list was generated from the DSS database
that contained the names of the heads of each household
in each cluster. The random number function in Excel
was then used to select 10 individual households from
the list for each of the 10 clusters.
Mosquitoes were collected using the indoor pyrethrum
spray catch method [22]. These collections were con-
ducted on one day each week between the hours of
07:00 and 10:00 AM to obtain those mosquitoes that
had fed on the inhabitants of the house during the previ-
ous night.
Determination of mosquito density, sporozoite index,
human biting rate and entomological inoculation rate (EIR)
All mosquitoes collected were transported to the labora-
tory where the abdomens of the females were examined
under a dissecting microscope to classify them into their
respective blood feeding stages: unfed, blood-fed, semi-
gravid, and gravid.
From each collection round, the head-thorax portion of
200 randomly selected blood-fed, semi-gravid and gravid
female Anopheles gambiae s.l. was dissected from the
abdomen. The random selection was done by using the
random number function in Excel to select mosquitoes on
the basis of the unique ID numbers given to each insect.
The head-thorax portions were tested by an enzyme-
linked immunosorbent assay (ELISA) that specifically
detects P. falciparum circumsporozoite protein (CSP)
antigen to allow estimation of the P. falciparum sporozoite
index according to the method described by Burkot et al.
(1984) and modified by Wirtz et al. (1987) [23,24]. To de-
termine the number of mosquitoes that had fed on
humans, an ELISA was performed on the abdomen por-
tions to screen for IgG in the blood meals [25].
Identification of mosquito species
All mosquitoes collected were morphologically identified.
In addition, molecular analysis was used to confirm the
morphological classification of An. gambiae s.l. for at least
100 insects from each collection. These were randomly se-
lected by ID number as previously described. Mosquitoes
positive for the ELISA P. falciparum CSP also underwent
molecular classification. Mosquitoes belonging to An. gam-
biae s.l. were identified to the species level using a standard
PCR technique as described by Fanello et al. [26].
Insecticide target site mutation (kdr) detection
A subsample of 500 An. gambiae s.l. mosquitoes (50
from each intervention and control cluster) were
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randomly selected from each collection (as described
above) to undergo testing by PCR according to
Martinez-Torres et al. (1998) and Ranson et al. (2000)
for detection of the kdr gene mutation that confers re-
sistance to pyrethroids [27,28]. To obtain an accurate
representation of the kdr allele frequency in each village
of the study area, all An. gambiae s.l. collected were eli-
gible for kdr screening regardless of whether they were
alive or dead.
Statistical methods
This study was analyzed at the cluster level, i.e. the clus-
ter was considered as an experimental unit and observa-
tions were based on individual subjects in each cluster.
All hypothesis testing, except human biting rate and
EIR, was conducted one-sided at a 0.05 level of signifi-
cance. No adjustments for multiplicity were performed.
To account for both the occurrence and timing of the
first RDT-confirmed symptomatic malaria episode with
a parasite density >5,000/μL (SMRC5000), survival ana-
lysis was carried out using PROC LIFETEST in SAS®, as-
suming hazard ratio remains constant over time, and
considering only the number of subjects at risk at that
time point of consideration as denominator. Time was
measured in days from the day of diagnosis of asymp-
tomatic carriage to first SMRC5000 in the study period.
The survival probability was estimated based on a
Kaplan-Meier estimate. Missing time was censored at
time of withdrawal or completion of the study period in-
cluding immigrant and emigrant subjects.
Mosquito density was expressed as the number of fe-
male mosquitoes collected per household. The human
biting rate was determined by dividing the number of
mosquitoes that had fed on humans by the number of
people who had slept in the house during the night be-
fore collection. From these data, the daily EIR was the
product of the human biting rate (number of bites/per-
son/night) and the proportion of sporozoite-positive
mosquitoes. The daily EIR was multiplied by the number
of days in the corresponding month to obtain an esti-
mate of the monthly EIR. Then, the monthly EIRs in
each arm were summed up to obtain the cumulative an-
nual EIR. To examine the influence of the intervention
on human biting rates and EIR, a two-sided Wilcoxon
rank sum test at 95% level of significance was adopted.
Results
Clinical study demographics and baseline characteristics
These results were reported previously by Tiono et al.
(2013) [21]. A total of 6,817 persons in the intervention
arm and 7,258 persons in the control arm were recruited
and enrolled in the clinical study (Figure 2). The inter-
vention and control arms were similar in terms of demo-
graphic characteristics with the exception of ethnicity;
the intervention arm had a higher proportion of Fulani
(8.7% vs 3.8%). Overall, 96.1% of the population in the
intervention arm who consented to participation were
tested by RDT and treated accordingly. The primary out-
comes of this study are reported in Tiono et al. (2013) [21].
Prevalence of asymptomatic carriers
The prevalence of asymptomatic carriage of asexual par-
asites over time is presented in Table 1. The mean per-
centage of carriers in the intervention arm was much
lower at campaign 2 and campaign 3 than in the control
arm, but showed only a small difference at campaign 4.
Incidence of first symptomatic malaria episodes in all ages
Kaplan-Meier analysis of the incidence of first SMRC5000
following screening campaign 3 showed that in the total
population the two treatment arms were similar until
Week 11–12, i.e. the beginning of the malaria transmission
season. After this time, the probability of being free of mal-
aria was lower in the intervention arm (logrank p <0.0001).
Similar trends were observed in infants and children <5
years (logrank p = 0.0356) and in individuals ≥5 years of
age (logrank p <0.0001; Figure 3, Additional file 1). Sub-
jects who discontinued before day 8 of screening campaign
3 were excluded from these analyses. Age was considered
on day 1 of screening campaign 1.
Figures 4 and 5 illustrate the distribution of P. falcip-
arum density during the different SMRC5000 episodes in
infants and children <5 years and in individuals aged ≥5
years of age. In infants and children <5 years of age who ex-
perienced symptomatic malaria episodes, the geometric
mean of P. falciparum density was lower in the intervention
arm than the control arm. The parasite density (parasites/
μL) in the intervention vs the control arm was 82,203 vs
104,120 during the first episode, 81,583 vs 95,248 during the
second episode, 88,599 vs 91,514 during the third episode,
and 83,532 vs 97,966 at any episode (Figure 4). This trend
was not seen in those individuals aged ≥5 years. The parasite
density in the intervention vs the control arm was 34,176 vs
33,614 during the first episode, 40,109 vs 37,499 during the
second episode, 47,225 vs 35,915 during the third episode,
and 35,783 vs 34,182 at any episode (Figure 5).
The proportion of individuals in the total population
carrying gametocytes during any clinical malaria episode
of any parasite density was 3.0% (95% CI 2.5% – 3.7%)
and 3.8% (95% CI 3.2% – 4.6%) respectively in the inter-
vention and the control arms. Similar patterns were ob-
served between arms when the participants were
stratified by age category.
Gametocyte density as measured by microscopy at the
end of the trial was at least 2-fold higher in the control
arm than in the intervention arm. When gametocyte
density was measured by qRT-PCR, the difference be-
tween the two arms was even greater (Figure 6).
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Table 1 Prevalence of microscopy-confirmed asymptomatic carriers of asexual parasites over time by study arm
Study arm Campaign 1/Day 1 Campaign 2/Day 1 Campaign 3/Day 1 Campaign 4/Day 1
Mean (SD)
Intervention 42.8 (5.67) 4.1 (1.62) 2.8 (0.92) 34.4 (3.92)
Control 47.5 (8.05) 35.7 (4.94) 32.2 (9.26) 37.8 (6.37)
Figure 2 Consort chart. Reproduced from Tiono et al. 2013 [21].
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Entomology study results
From January to December 2011, a total of 12,466 mos-
quitoes were collected across the 10 clusters (6,677 in
the control arm and 5,789 in the intervention arm). The
species composition collected in the two arms of the
study was similar (Table 2). The frequency of the kdr
gene mutation was slightly higher in the control arm
(0.71; SD 0.16) than the intervention arm (0.65; SD
0.12). The intervention arm mean (SD) biting rate was
1.12 (1.20) bites per person per night, vs 1.12 (1.19) bites
per person per night in the control arm. Over the year,
EIR and mosquito density results were also comparable
in both arms, with peaks for both observed in September
(Table 3, Figure 7). Although the monthly EIR appeared
to be slightly higher in the intervention arm than the
control arm throughout the study period (except
Figure 3 Kaplan-Meier plot of incidence of first SMRC5000 following screening campaign 3 – cluster level data.
Figure 4 Distribution of P. falciparum density during SMRC5000 in infants and children <5 years of age following screening campaign 3.
I = intervention arm; C = control arm; numbers 1–3 indicate first, second and third episodes, and A any episode; n = number of subjects at each
episode; central rectangles span the first quartile to the third quartile (IQR); the line inside each rectangle shows the median; the whiskers that
extend from each box indicate the range of values that are outside of the intra-quartile range but close enough not to be considered outliers
(a distance less than or equal to 1.5*IQR); ♦ = geometric mean.
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September, when it was slightly lower in intervention
arm), the difference was not statistically significant (p =
0.7086, considering all 12 months). Similar results were
also obtained considering only the months July to
December (p = 0.8182).
Discussion
Community screening and targeted treatment of asymp-
tomatic carriers of P. falciparum malaria was associated
with a negative impact on the incidence of first symp-
tomatic malaria episode with a parasite density >5,000/
μL. The probability of developing a first episode of
symptomatic malaria was higher in the intervention arm
than in the control arm; however, the cumulative inci-
dence of malaria was similar in both arms (Tiono et al.
2013) [21].
The results may suggest that clearance of asymptom-
atic infections increases an individual’s risk of contract-
ing a symptomatic malaria episode. A similar ‘rebound’
effect has been observed following the use of chemo-
prophylaxis in malaria-endemic areas [29-31]. It has
been proposed that asymptomatic carriage might be a
form of tolerance to P. falciparum infection that pro-
tects against the development of clinical episodes [32].
Figure 5 Distribution of P. falciparum density during SMRC5000 in individuals ≥5 years of age following screening campaign 3.
I = intervention arm; C = control arm; numbers 1–3 indicate first, second and third episodes, and A any episode; n = number of subjects at each
episode; central rectangles span the first quartile to the third quartile (IQR); the line inside each rectangle shows the median; the whiskers that
extend from each box indicate the range of values that are outside of the intra-quartile range but close enough not to be considered outliers
(a distance less than or equal to 1.5*IQR); ♦ = geometric mean.
Figure 6 Mean P. falciparum gametocyte density at screening campaign 4.
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Consequently, clearance of these infections might have
rendered individuals more susceptible to reinfection and
development of clinical malaria. A number of reports
have also indicated that while semi-immunity to malaria
can be acquired in highly endemic areas by the age of 5
years, this immunity wanes rapidly without ongoing
parasite exposure [33,34]. As shown in Figure 3, children
<5 years of age, individuals of at least 5 years of age and
the total population were all at risk of developing a
symptomatic malaria episode with a parasite density
>5,000/μL after the three screening campaigns. These
findings seem to confirm that in the absence of contin-
ual exposure, any immunity an individual has acquired
to clinical disease is relatively short-lived.
The development of clinical and parasitological im-
munity to malaria is marked by the ability of individuals
to control disease and parasite density [34]. In this study,
children in the intervention arm <5 years of age tended
to develop clinical signs and symptoms at lower parasite
densities than their peers in the control arm; a situation
that was reversed in older children and adults. While it
is difficult to draw conclusions from these findings, it is
possible that, overall, the treatment of asymptomatic car-
riers had some effect on the development of immunity
that may differ with the age of the subject. In younger
children in the intervention arm, this effect on immunity
seemed to make them more susceptible to symptomatic
disease (or more likely to notice its signs and symptoms)
at lower parasite densities. However, it may also be that
the lower parasite density reflects only an earlier diagno-
sis of disease due to the fact that the caregivers of young
children in the intervention arm were more prompt to
report to their healthcare facility upon the first signs of
illness. In older children and adults, the treatment ap-
pears to affect the ability to control parasite density, sug-
gesting possible interference with the anti-parasite
immunity which is known to restrict the density of asex-
ual parasitemia.
Among other factors, malaria transmission depends on
the presence of infectious sexual parasites (gametocytes)
in human peripheral blood. While individuals with sub-
patent gametocytemia are able to infect mosquitoes, pre-
vious research carried out in Burkina Faso has shown
that individuals with microscopically detected gameto-
cytes are two-fold more likely to be infectious compared
to those with submicroscopic gametocytes (68.2% vs
31.7%; p = 0.001) [35]. Although gametocyte density in
our study was far greater in the control arm compared
to the intervention arm, transmission indices were
Table 2 Entomological results by study arm
Intervention Control
Mosquito species
Anopheles gambiae s.l. 91.7% 92.7%
Anopheles funestus 0.1% 0.2%
Other Anopheles 0.6% 0.4%
Culex 7.4% 6.5%
Aedes 0.2% 0.2%
Anopheles gambiae s.l. composition
Anopheles arabiensis 13% 14%
Anopheles coluzzi 61% 57%
Anopheles gambiae 26% 28%
Frequency of kdr West African mutation (SD) 0.65 (0.12) 0.71 (0.16)
Mean number of mosquitoes/house (SD) 6.30 (5.89) 5.96 (2.67)
Mean number of bites/person/night (SD) 1.12 (1.20) 1.12 (1.19)
EIR (i.e. cumulative number of infective
bites/person/year)
39.46 31.42
Table 3 Monthly variation of entomological indices in study arms
Number of fed mosquitoes
collected
Human blood index Mean human biting rate
(number of bites/person/night)
Sporozoite index
Month Intervention Control Intervention Control Intervention Control Intervention Control
January 1 15 0.00 1.00 0.00 0.24 0.00 0.00
February 29 48 0.83 0.85 0.08 0.15 0.06 0.03
March 35 144 1.00 0.92 0.22 0.75 0.00 0.00
April 9 37 1.00 1.00 0.04 0.32 0.00 0.00
May 261 189 1.00 1.00 1.58 1.03 0.01 0.00
June 492 634 0.97 0.86 1.89 1.65 0.03 0.02
July 610 630 0.93 0.75 2.07 1.77 0.05 0.04
August 712 808 0.96 0.96 1.84 1.89 0.19 0.16
September 993 1238 0.98 0.90 3.83 4.23 0.13 0.12
October 502 413 0.99 0.92 1.46 1.25 0.17 0.10
November 122 78 0.93 0.80 0.41 0.19 0.13 0.08
December 3 3 1.00 1.00 0.02 0.04 0.16 0.00
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similar in both arms. This suggests that there was no dif-
ference in transmission ecology between the study arms,
and that transmission potential of individuals in the
intervention arm was not affected by the screening and
treatment. Moreover, although not supported by these
results, an enhanced post-treatment transmission poten-
tial in the absence of a change in transmission dynamic
in the intervention arm cannot be excluded. It is known
that the presence of immunity to P. falciparum sexual
stages is an essential factor for reducing human-to-
mosquito transmission of malaria parasites by prevent-
ing the fertilization and development of the parasite in
the mosquito midgut. In addition, it has been shown in
previous work that naturally acquired immunity against
Pfs48/45 and Pfs230 (antigens specific to the sexual
stages of P. falciparum) is a function of recent exposure
rather than of cumulative exposure to gametocytes
[36]. Therefore, with the known gametocidal effect of
artemether-lumefantrine on immature gametocytes
and the significant reduction of gametocyte preva-
lence in the intervention vs the control arm following
the screening campaigns, it is possible that immunity
against Pfs48/45 and Pfs230 could be impaired, thus
increasing the infectivity of treated individuals to the
mosquitoes.
A potential confounding factor is the invasion of inter-
vention clusters by infected mosquitoes from surround-
ing villages that did not receive LLINs and thereby
contributed to the spread of infection; however, as such
invasion is also likely to occur in the control clusters the
effect of this factor on the overall results is likely to be
marginal. Additionally, RDT sensitivity (vs microscopy)
during the three screening campaigns was 92.4%, 84.0%
and 77.8%. These findings suggest that by using RDT
and subsequent microscopic confirmation a notable pro-
portion of asymptomatic carriers were undetected. The
use of more sensitive molecular techniques, possibly in
combination with RDT, may merit exploration in future
mass screening and treatment interventions.
Overall, the malaria transmission dynamic in the study
arms is comparable to previous reports from the area
[37]. The human biting rates observed in our study at
the September peak (3.83 in the intervention arm and
4.23 in the control arm) were far lower than the 26.7
bites/person/night that was previously reported in the
area [36]. This is probably due to the high coverage of
the study population with LLINs and the reduction in
mosquito aggressiveness following mass bednet use
[38,39]. The prevalence of kdr mutation observed was
comparable to that observed in 2010 by Badolo et al. in
a village located 30 km from Ouagadougou with the
same agricultural practices as the study area [40].
Conclusion
Community screening and targeted treatment of asymp-
tomatic carriers of P. falciparum seemed to be associ-
ated with an increase in the treated community’s
susceptibility to malaria episodes once the screening
campaigns had finished. In the context of malaria elim-
ination, these results clearly show the importance of fur-
ther exploratory studies to better understand the
dynamics of disease transmission and possible immuno-
logical factors involved. They also underline the fact that
clearing the reservoir of malaria parasites with effective
antimalarial drugs might not be enough to interrupt
malaria transmission in high-transmission settings; asso-
ciation with malaria transmission-blocking tools might
be required. In the absence of an effective malaria
transmission-blocking vaccine, drugs with known
transmission-blocking potential such as primaquine [41]
and ivermectin [42] might have a significant role to play
in this regard, and this should be explored.
Figure 7 Temporal variation of Anopheles density and entomological inoculation rate (EIR) by study arm.
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